These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 26645223)
1. Therapies to Preserve β-Cell Function in Type 1 Diabetes. Ludvigsson J Drugs; 2016 Feb; 76(2):169-85. PubMed ID: 26645223 [TBL] [Abstract][Full Text] [Related]
2. Novel therapies in the management of type I diabetes mellitus. Ludvigsson J Panminerva Med; 2012 Dec; 54(4):257-70. PubMed ID: 23123577 [TBL] [Abstract][Full Text] [Related]
3. Immune intervention at diagnosis--should we treat children to preserve beta-cell function? Ludvigsson J Pediatr Diabetes; 2007 Oct; 8 Suppl 6():34-9. PubMed ID: 17727383 [TBL] [Abstract][Full Text] [Related]
4. GAD65: a prospective vaccine for treating Type 1 diabetes? Ludvigsson J Expert Opin Biol Ther; 2017 Aug; 17(8):1033-1043. PubMed ID: 28480759 [TBL] [Abstract][Full Text] [Related]
5. The role of immunomodulation therapy in autoimmune diabetes. Ludvigsson J; J Diabetes Sci Technol; 2009 Mar; 3(2):320-30. PubMed ID: 20144363 [TBL] [Abstract][Full Text] [Related]
6. GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion. Ludvigsson J Expert Opin Biol Ther; 2010 May; 10(5):787-99. PubMed ID: 20230187 [TBL] [Abstract][Full Text] [Related]
7. Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Besançon A; Goncalves T; Valette F; Dahllöf MS; Mandrup-Poulsen T; Chatenoud L; You S Diabetologia; 2018 Feb; 61(2):389-398. PubMed ID: 29030662 [TBL] [Abstract][Full Text] [Related]
8. A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Gill RG; Pagni PP; Kupfer T; Wasserfall CH; Deng S; Posgai A; Manenkova Y; Bel Hani A; Straub L; Bernstein P; Atkinson MA; Herold KC; von Herrath M; Staeva T; Ehlers MR; Nepom GT Diabetes; 2016 May; 65(5):1310-6. PubMed ID: 26718498 [TBL] [Abstract][Full Text] [Related]
9. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients. Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J Front Immunol; 2020; 11():564921. PubMed ID: 33162978 [TBL] [Abstract][Full Text] [Related]
10. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. Diaz-de-Durana Y; Lau J; Knee D; Filippi C; Londei M; McNamara P; Nasoff M; DiDonato M; Glynne R; Herman AE PLoS One; 2013; 8(10):e78483. PubMed ID: 24205242 [TBL] [Abstract][Full Text] [Related]
11. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F; N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093 [TBL] [Abstract][Full Text] [Related]
12. Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes. Kroger CJ; Clark M; Ke Q; Tisch RM Front Immunol; 2018; 9():1891. PubMed ID: 30166987 [TBL] [Abstract][Full Text] [Related]
13. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Rother KI; Spain LM; Wesley RA; Digon BJ; Baron A; Chen K; Nelson P; Dosch HM; Palmer JP; Brooks-Worrell B; Ring M; Harlan DM Diabetes Care; 2009 Dec; 32(12):2251-7. PubMed ID: 19808924 [TBL] [Abstract][Full Text] [Related]
14. Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes. Rydén AK; Perdue NR; Pagni PP; Gibson CB; Ratliff SS; Kirk RK; Friesen TJ; Haase C; Coppieters K; von Herrath MG; Boursalian TE J Autoimmun; 2017 Nov; 84():65-74. PubMed ID: 28711285 [TBL] [Abstract][Full Text] [Related]
15. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives. Fändrich F; Ungefroren H Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518 [TBL] [Abstract][Full Text] [Related]
16. Immune therapy and β-cell death in type 1 diabetes. Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576 [TBL] [Abstract][Full Text] [Related]
17. The potential of incretin-based therapies in type 1 diabetes. Suen CS; Burn P Drug Discov Today; 2012 Jan; 17(1-2):89-95. PubMed ID: 21920456 [TBL] [Abstract][Full Text] [Related]
18. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Liu EH; Digon BJ; Hirshberg B; Chang R; Wood BJ; Neeman Z; Kam A; Wesley RA; Polly SM; Hofmann RM; Rother KI; Harlan DM Diabetologia; 2009 Jul; 52(7):1369-80. PubMed ID: 19418039 [TBL] [Abstract][Full Text] [Related]
19. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Sherry NA; Chen W; Kushner JA; Glandt M; Tang Q; Tsai S; Santamaria P; Bluestone JA; Brillantes AM; Herold KC Endocrinology; 2007 Nov; 148(11):5136-44. PubMed ID: 17673522 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D. Boettler T; von Herrath M Int Immunopharmacol; 2010 Dec; 10(12):1491-5. PubMed ID: 20667487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]